B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
Clinical trials for B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New targeted therapy aims to beat back childhood leukemia relapse
Disease control Recruiting nowThis study tests a drug called inotuzumab ozogamicin (Besponsa) against standard chemotherapy for children aged 1 to 17 with high-risk B-cell acute lymphoblastic leukemia that has returned after initial treatment. The goal is to see if the targeted drug can clear more cancer cell…
Matched conditions: B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Two-Drug combo aims to wipe out childhood leukemia faster
Disease control Recruiting nowThis study tests whether giving two targeted immunotherapy drugs (inotuzumab and blinatumomab) together at the start of treatment can eliminate leukemia cells more effectively than standard chemotherapy in children and young adults (ages 1-18) with newly diagnosed B-cell acute ly…
Matched conditions: B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New CAR T-Cell therapy targets tough blood cancers
Disease control Recruiting nowThis study tests a new treatment called SHB-04-CD22, which uses a patient's own immune cells (T-cells) engineered to find and attack cancer cells that have a protein called CD22. It is for children and adults (ages 1-80) with B-cell cancers that have come back or not responded to…
Matched conditions: B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Sheba Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Immunotherapy Follow-Up study launched for young cancer patients
Knowledge-focused Recruiting nowThis study follows up to 500 children and young adults (up to age 26) with B-cell leukemia or lymphoma who have received immunotherapy like Kymriah or blinatumomab. Researchers will use surveys and medical records to track survival, remission, and unmet needs. No new treatment is…
Matched conditions: B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC